{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:40:56Z","timestamp":1792201256683,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vaccine.2023.10.019","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T19:40:22Z","timestamp":1697830822000},"page":"7129-7137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immunogenicity of rabies virus G mRNA formulated with lipid nanoparticles and nucleic acid immunostimulators in mice"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4587-0791","authenticated-orcid":false,"given":"Qiao","family":"Hongtu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"BoLi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Jianguo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Shusheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.10.019_b0005","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","article-title":"Rabies","volume":"3","author":"Fooks","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"6592","key":"10.1016\/j.vaccine.2023.10.019_b0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1126\/science.abn0713","article-title":"Rabies shows how scale of transmission can enable acute infections to persist at low prevalence","volume":"376","author":"Mancy","year":"2022","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.vaccine.2023.10.019_b0015","doi-asserted-by":"crossref","first-page":"e0009617","DOI":"10.1371\/journal.pntd.0009617","article-title":"Rabies epidemiology, prevention and control in Nigeria: Scoping progress towards elimination","volume":"15","author":"Mshelbwala","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.10.019_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.prevetmed.2020.105161","article-title":"Regional and age difference of human rabies prevalence of the past fourteen years in China","volume":"187","author":"Qiao","year":"2021","journal-title":"Prev Vet Med"},{"issue":"11","key":"10.1016\/j.vaccine.2023.10.019_b0025","first-page":"1201","article-title":"Epidemiology of Rabies and the Control Challenges","volume":"2","author":"Habib","year":"2020","journal-title":"Biotica Res Today"},{"key":"10.1016\/j.vaccine.2023.10.019_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.lansea.2023.100258","article-title":"Rabies control in high-burden countries: role of universal pre-exposure immunization","author":"Lodha","year":"2023","journal-title":"Lancet Regional Health-Southeast Asia"},{"issue":"7","key":"10.1016\/j.vaccine.2023.10.019_b0035","doi-asserted-by":"crossref","first-page":"taaa006","DOI":"10.1093\/jtm\/taaa006","article-title":"Intradermal rabies pre-exposure vaccination schedules in older travellers: comparison of immunogenicity post-primary course and post-booster","volume":"27","author":"Furuya-Kanamori","year":"2020","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2023.10.019_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.onehlt.2020.100161","article-title":"One-health approach: A best possible way to control rabies","volume":"10","author":"Acharya","year":"2020","journal-title":"One Health"},{"key":"10.1016\/j.vaccine.2023.10.019_b0045","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1016\/j.vaccine.2019.04.024","article-title":"Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017\u20132018","volume":"37","author":"Sreenivasan","year":"2019","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.019_b0050","first-page":"185","article-title":"Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children","volume":"17","author":"Angsuwatcharakon","year":"2018","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2023.10.019_b0055","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/clinids\/20.3.646","article-title":"Immunogenicity of purified duck embryo rabies vaccine (Lyssavac-N) with use of the WHO-approved intradermal postexposure regimen","volume":"20","author":"Khawplod","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.10.019_b0060","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2165\/00003495-199856050-00005","article-title":"Current recommendations for the prophylaxis and treatment of rabies","volume":"56","author":"Dreesen","year":"1998","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.019_b0065","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vaccine.2009.09.090","article-title":"A comparative study on the safety and immunogenicity of purified duck embryo cell vaccine (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab)","volume":"28","author":"Ashwathnarayana","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2023.10.019_b0070","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/vaccines7020054","article-title":"New rabies vaccines for use in humans","volume":"7","author":"Ertl","year":"2019","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2023.10.019_b0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2012.04592.x","article-title":"Developments in rabies vaccines","volume":"169","author":"Hicks","year":"2012","journal-title":"Clin Exp Immunol"},{"issue":"37","key":"10.1016\/j.vaccine.2023.10.019_b0080","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","article-title":"Rabies vaccines: WHO position paper, April 2018\u2013Recommendations","volume":"36","author":"Organization","year":"2018","journal-title":"Vaccine"},{"issue":"7872","key":"10.1016\/j.vaccine.2023.10.019_b0085","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.vaccine.2023.10.019_b0090","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2\u2014preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2023.10.019_b0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.vaccine.2023.10.019_b0100","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol"},{"key":"10.1016\/j.vaccine.2023.10.019_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.019_b0110","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1084\/jem.145.6.1617","article-title":"Suppression of cell-mediated immunity by street rabies virus","volume":"145","author":"Wiktor","year":"1977","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2023.10.019_b0115","doi-asserted-by":"crossref","first-page":"108890","DOI":"10.1016\/j.vetmic.2020.108890","article-title":"Newcastle disease virus vectored rabies vaccine induces strong humoral and cell mediated immune responses in mice","volume":"251","author":"Debnath","year":"2020","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2023.10.019_b0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fimmu.2019.00179","article-title":"Immunostimulatory activities of CpG-oligodeoxynucleotides in teleosts: toll-like receptors 9 and 21","volume":"10","author":"Lai","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.019_b0125","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.apsb.2021.06.006","article-title":"Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer","volume":"12","author":"Fang","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.vaccine.2023.10.019_b0130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-0716-0872-2_4","article-title":"CpG oligonucleotides as vaccine adjuvants","author":"Kayraklioglu","year":"2021","journal-title":"DNA Vacc: Methods Protoc"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.019_b0135","doi-asserted-by":"crossref","first-page":"14661","DOI":"10.1038\/s41598-021-94250-0","article-title":"Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy","volume":"11","author":"Yazdani","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.10.019_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109494","article-title":"Repeat exposure to polyinosinic: polycytidylic acid induces TLR3 expression via JAK-STAT signaling and synergistically potentiates NF\u03baB-RelA signaling in ARPE-19 cells","volume":"66","author":"Duncan","year":"2020","journal-title":"Cell Signal"},{"issue":"12","key":"10.1016\/j.vaccine.2023.10.019_b0145","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.4161\/cbt.10.12.13450","article-title":"Anticancer function of polyinosinic-polycytidylic acid","volume":"10","author":"Cheng","year":"2010","journal-title":"Canc Biol Therapy"},{"issue":"6","key":"10.1016\/j.vaccine.2023.10.019_b0150","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.vaccine.2023.10.019_b0155","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.vaccine.2023.10.019_b0160","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMc2113468","article-title":"SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2023.10.019_b0165","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/01410768211053006","article-title":"The costs of coronavirus vaccines and their pricing","volume":"114","author":"Light","year":"2021","journal-title":"J R Soc Med"},{"issue":"8","key":"10.1016\/j.vaccine.2023.10.019_b0170","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3390\/pr9081430","article-title":"Adenoviral vector COVID-19 vaccines: Process and cost analysis","volume":"9","author":"Ferreira","year":"2021","journal-title":"Processes"},{"issue":"3","key":"10.1016\/j.vaccine.2023.10.019_b0175","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/tid.12393","article-title":"Clinical management and humoral immune responses to rabies post-exposure prophylaxis among three patients who received solid organs from a donor with rabies","volume":"17","author":"Vora","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2023.10.019_b0180","article-title":"Humoral immune response of Thai dogs after oral vaccination against rabies with the SPBN GASGAS vaccine strain","volume":"8","author":"Leelahapongsathon","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.10.019_b0185","doi-asserted-by":"crossref","first-page":"735","DOI":"10.20506\/rst.11.3.622","article-title":"Practical significance of rabies antibodies in cats and dogs","volume":"11","author":"Aubert","year":"1992","journal-title":"Revue Scientifique et Technique-Office International des Epizooties"},{"key":"10.1016\/j.vaccine.2023.10.019_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2022.101204","article-title":"Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy","volume":"53","author":"de Melo","year":"2022","journal-title":"Curr Opin Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2023.10.019_b0195","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/QCO.0000000000000578","article-title":"WHO's new rabies recommendations: implications for high incidence countries","volume":"32","author":"Pattanaik","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.10.019_b0200","unstructured":"Behera TR and Ashe S. Safety and immunogenicity of Rabies Human Monoclonal Antibody (Rabishield) in a category III rabid dog bite: A case report. APCRI J: p. 40."},{"key":"10.1016\/j.vaccine.2023.10.019_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104956","article-title":"Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects","volume":"184","author":"Ding","year":"2020","journal-title":"Antiviral Res"},{"issue":"9","key":"10.1016\/j.vaccine.2023.10.019_b0210","doi-asserted-by":"crossref","first-page":"e2722","DOI":"10.1093\/cid\/ciaa779","article-title":"A Phase 3, randomized, open-label, noninferiority trial evaluating anti-rabies monoclonal antibody cocktail (TwinrabTM) against human rabies immunoglobulin (HRIG)","volume":"73","author":"Kansagra","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.019_b0215","first-page":"35","article-title":"Monoclonal antibodies for rabies post-exposure prophylaxis: a paradigm shift in passive immunization","volume":"5","author":"Gongal","year":"2020","journal-title":"Arch Prev Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.019_b0220","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12985-022-01919-7","article-title":"An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs","volume":"19","author":"Li","year":"2022","journal-title":"Virol J"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.019_b0225","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1038\/s41467-023-39421-5","article-title":"Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses","volume":"14","author":"Hellgren","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.10.019_b0230","first-page":"169","article-title":"Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine","volume":"63","author":"Andre","year":"1987","journal-title":"Postgrad Med J"},{"issue":"10","key":"10.1016\/j.vaccine.2023.10.019_b0235","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/00003495-200363100-00006","article-title":"Recombinant Hepatitis B Vaccine (Engerix-B\u00ae) A Review of its Immunogenicity and Protective Efficacy Against Hepatitis B","volume":"63","author":"Keating","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2023.10.019_b0240","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B\u00ae HBV vaccine in healthy adults: A double-blind phase I\/II study","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.019_b0245","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.vaccine.2023.10.019_b0250","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2023.10.019_b0255","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/vaccines7030110","article-title":"The cellular immune response to rabies vaccination: a systematic review","volume":"7","author":"Overduin","year":"2019","journal-title":"Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2301191X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2301191X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T20:09:36Z","timestamp":1720037376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2301191X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":51,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0264410X2301191X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of rabies virus G mRNA formulated with lipid nanoparticles and nucleic acid immunostimulators in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}